|
|
|
 = Add Release to Briefcase |
| All Releases |
|---|
 |
Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimer's Disease
Jul 17, 2008
|
13.2 KB
|
| |
SAN FRANCISCO, July 17, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced publication of the results of its first Alzheimer's disease pivotal clinical trial of the investigational drug Dimebon in the July 19, 2008 issue of The Lancet. In this double-blind, placebo-controlled trial, patients with ...
|
|
|
Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntington's Disease
Jul 7, 2008
|
12.8 KB
|
| |
SAN FRANCISCO, July 7, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced top-line results of a Phase 2 study showing that its investigational drug Dimebon(TM) significantly improved cognitive function in patients with mild-to-moderate Huntington's disease (HD). Cognitive function was significantl...
|
|
|
Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntington's Disease
Jul 3, 2008
|
9.0 KB
|
| |
SAN FRANCISCO, July 3, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will hold a teleconference at 5:00 p.m. EDT on Monday, July 7, to discuss top-line results from its randomized, double-blind, placebo-controlled Phase 2 clinical trial of dimebon(TM) in Huntington's disease.
Tele...
|
|
|
Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimer's Disease
Jun 9, 2008
|
12.1 KB
|
| |
SAN FRANCISCO, June 9, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced it has initiated dosing of patients in its second pivotal Phase 3 trial of the investigational drug Dimebon(TM) in patients with mild-to-moderate Alzheimer's disease (AD). The international, double-blind, placebo-controlled ...
|
|
|
Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
Jun 2, 2008
|
12.0 KB
|
| |
SAN FRANCISCO and CHICAGO, June 2, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that data from an ongoing Phase 1-2 clinical trial of the Company's novel androgen receptor antagonist, MDV3100, showed encouraging anti-tumor activity as measured by declining serum levels of prostate specific a...
|
|
|
Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
May 15, 2008
|
10.4 KB
|
| |
SAN FRANCISCO, May 15, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that data from an ongoing Phase 1-2 clinical trial of its novel androgen receptor antagonist, MDV3100, will be presented in an oral presentation at the 44th American Society of Clinical Oncology (ASCO) Annual Meeting in Chic...
|
|
|
Medivation Announces Participation in Upcoming Conferences
May 13, 2008
|
8.1 KB
|
| |
SAN FRANCISCO, May 13, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the following conferences.
-- Rodman & Renshaw 5th Annual Global Healthcare Conference on Tuesday,
May 20 at 2:40 p.m. local tim...
|
|
|
Medivation Reports First Quarter 2008 Financial Results and Provides Corporate Update
May 1, 2008
|
16.2 KB
|
| |
SAN FRANCISCO, May 1, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today reported on its corporate progress and financial results for the quarter ended March 31, 2008.
"We are dedicated to developing product candidates as rapidly, efficiently and cost-effectively as possible, as patients are in desperat...
|
|
|
Medivation Announces Participation in Upcoming Conferences
Apr 30, 2008
|
8.1 KB
|
| |
SAN FRANCISCO, April 30, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the following conferences.
-- Deutsche Bank 33rd Annual Health Care Conference on Monday, May 5 at
2:00 p.m. Eastern Time at T...
|
|
|
Medivation Announces First Quarter 2008 Teleconference and Webcast on May 1, 2008
Apr 24, 2008
|
7.8 KB
|
| |
SAN FRANCISCO, April 24, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will webcast a teleconference with management to discuss first quarter 2008 progress and provide a general business update on Thursday, May 1, 2008, at 4:30 p.m. Eastern time. A financial results press release for ...
|
|
| |
AAN abstract for April 17
Apr 17, 2008
|
17.7 KB
|
|
Medivation's Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimer's Disease Patients Over One Year
Apr 17, 2008
|
12.0 KB
|
| |
SAN FRANCISCO and CHICAGO, April 17, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that Alzheimer's patients treated with the investigational drug Dimebon(TM) showed improvement in the key aspects of cognitive function over a one-year period compared with placebo. The improvement occurred in ...
|
|
| |
AAN abstract for April 15
Apr 15, 2008
|
15.9 KB
|
|
Medivation's Dimebon(TM) Significantly Improved Daily Function in Alzheimer's Disease Patients, Resulting in Reduced Need for Caregiver Assistance
Apr 15, 2008
|
12.2 KB
|
| |
SAN FRANCISCO and CHICAGO, April 15, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that Alzheimer's patients taking the investigational drug Dimebon(TM) showed significant improvement in their ability to perform daily tasks over a one-year period compared to placebo. This improvement allowed ...
|
|
| |
2008 AACR Annual Meeting Abstract
Apr 14, 2008
|
18.8 KB
|
|
Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients
Apr 14, 2008
|
10.8 KB
|
| |
SAN FRANCISCO and SAN DIEGO, April 14, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that data from an ongoing Phase 1-2 clinical trial showed that the Company's novel androgen receptor antagonist, MDV3100, continued to reduce serum levels of prostate specific antigen (PSA), a marker of tumor...
|
|
|
Medivation Announces Senior Management Promotions
Mar 25, 2008
|
10.4 KB
|
| |
SAN FRANCISCO, March 25, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced the promotions of Michele D. Bronson, Ph.D., to vice president, regulatory and quality, Mohammad Hirmand, M.D., to vice president, clinical development, and Joyce Mordenti, Ph.D., to vice president, translational medicine....
|
|
|
Medivation's Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimer's Disease Patients, Resulting in Reduced Caregiver Distress
Mar 15, 2008
|
11.3 KB
|
| |
SAN FRANCISCO and ORLANDO, Fla., March 15, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that clinical results from its first pivotal trial of Dimebon(TM) showed that behavioral symptoms were stabilized in patients with mild-to-moderate Alzheimer's disease (AD) over a one-year period, resulti...
|
|
|
Medivation to Present at Cowen and Company's 28th Annual Health Care Conference
Mar 13, 2008
|
7.7 KB
|
| |
SAN FRANCISCO, March 13, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at Cowen and Company's 28th Annual Health Care Conference on Thursday, March 20, at 11:00 a.m. Eastern Time at The Boston Marriott Copley Place in ...
|
|
|
Medivation Announces First Presentation of Dimebon(TM) Behavioral and Caregiver Impact Data at Annual Meeting of American Association for Geriatric Psychiatry
Mar 12, 2008
|
8.9 KB
|
| |
SAN FRANCISCO, March 12, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that subdomain data on the effect of Dimebon(TM) on behavioral symptoms in patients with mild-to-moderate Alzheimer's disease and the impact on caregivers will be presented for the first time at the annual meeting of the A...
|
|
|
The press releases may contain historical information and may no longer be accurate. Medivation disclaims any responsibility to update such information.
|
 Briefcase
 Download Library
 Email Alerts
 RSS News Feeds
Amanda Mason
WeissComm Partners
1251 6th Ave.
Suite 3500
New York, NY 10020
Phone: 212-301-7221
Fax: 212-867-3249
For a high resolution copy of our logo (eps file), click here.
|
